Diabetic Gastroparesis Pipeline Insight
DelveInsight’s, “Diabetic Gastroparesis - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Diabetic Gastroparesis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Diabetic Gastroparesis Understanding
Diabetic Gastroparesis: Overview
Diabetic Gastroparesis refers to cases of the digestive condition gastroparesis that is caused by diabetes. The symptoms of gastroparesis vary in severity from person to person and may include any combination of the nausea and vomiting, heartburn, loss of appetite, weight loss, bloating, unstable blood sugar levels, gastroesophageal reflux and/or stomach spasms. Gastroparesis is more common in females than males, and in people who have had surgery around the esophagus, stomach, or small intestine, as surgery can affect the vagus nerve. The American College of Gastroenterology (ACG) guidelines for the diagnosis and management of Diabetic Gastroparesis state that a combination of appropriate symptoms and signs, along with delayed gastric emptying in the absence of gastric outlet obstruction or ulceration, is required to establish the diagnosis of Diabetic Gastroparesis. The treatments for Diabetic Gastroparesis include nutritional assessment and dietary modifications, glycemic control, prokinetic agents and antiemetic agents.
"Diabetic Gastroparesis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Gastroparesis pipeline landscape is provided which includes the disease overview and Diabetic Gastroparesis treatment guidelines. The assessment part of the report embraces, in depth Diabetic Gastroparesis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Gastroparesis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Gastroparesis R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Gastroparesis.
Diabetic Gastroparesis Emerging Drugs Chapters
This segment of the Diabetic Gastroparesis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Gastroparesis Emerging Drugs
Nimacimab: Bird Rock Bio
Nimacimab is a first-in-class peripheral antagonist antibody to cannabinoid receptor 1 (CB1) for the treatment of fibrotic, metabolic, and inflammatory diseases including nonalcoholic steatohepatitis (NASH) and diabetic kidney disease (DKD). The drug is in Phase II clinical studies for the treatment of Diabetic Gastroparesis.
NG101 is a potent, selective and peripherally restricted dopamine D2 receptor antagonist. The drug is in Phase II clinical evaluation for the treatment of Diabetic Gastroparesis. Neurogastrx has generated preclinical data indicating that in addition to its potent antiemetic properties, NG101 is also expected to significantly increase gastric motility, conferring NG101 an ideal pharmacological profile for the treatment of gastroparesis.
Further product details are provided in the report……..
Diabetic Gastroparesis: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Gastroparesis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic Gastroparesis
There are approx. 10+ key companies which are developing the therapies for Diabetic Gastroparesis. The companies which have their Diabetic Gastroparesis drug candidates in the most advanced stage, i.e. Phase III include, Vanda Pharmaceuticals.
DelveInsight’s report covers around 8+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Diabetic Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Diabetic Gastroparesis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Diabetic Gastroparesis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Gastroparesis drugs.
Diabetic Gastroparesis Report Insights
- Diabetic Gastroparesis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Diabetic Gastroparesis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic Gastroparesis drugs?
- How many Diabetic Gastroparesis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Gastroparesis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Gastroparesis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic Gastroparesis and their status?
- What are the key designations that have been granted to the emerging drugs?